Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome Inc.

In a report released today, Chad Messer from Lake Street maintained a Buy rating on Immunome, with a price target of $22.00. Messer covers the Heal...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMNM	$19.57	+0.41%	1.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMNM	$19.57	+0.4%	1.42M
3
4
5
6

IMNM

IMNM

Dividend Overview

Get Immunome Inc. Data in Excel

Get Immunome Inc. Data in Excel